Regulatory capacity becomes a leadership issue before it becomes a hiring issue
For growing healthcare and life sciences organizations, regulatory strain rarely shows up first as an empty seat. It usually appears as pressure on submission calendars, rising coordination demands across quality and clinical teams, and tighter review deadlines that leave less room for rework. That is why the practical question is not simply how many people are on staff, but whether the organization has the right regulatory capacity for the work in front of it.
FDA’s published resource-capacity framework is useful here because it defines planning as a method for matching the number and type of resources to forecasted workload. The agency also explains that forecasting supports timely review of incoming submissions. In staffing terms, that points employers toward role design based on workload, complexity, and deadlines rather than headcount alone.
For companies deciding when to bring in regulatory consultants, the implication is straightforward: capacity becomes critical when the regulatory function can no longer absorb forecast work without risking timing, quality, or cross-functional execution.
FDA data show why workload-based staffing matters
Recent FDA performance data underline how substantial the operating environment can be. As of September 30, 2025, FDA reported 2,283 completed actions for the FY 2025 PDUFA cohort, with another 1,672 submissions still under review and within their goal dates. That combination reflects both throughput and continuing active workload rather than a static review pipeline.
The same report shows heavy procedural activity around sponsor interaction. In FY 2025, FDA logged 238 Type A meeting requests, 2,016 Type B requests, 309 Type B end-of-phase requests, 1,534 Type C requests, 873 Type D requests, and 217 INTERACT requests. For employers, those figures are a reminder that regulatory demand extends beyond formal applications to meeting strategy, briefing preparation, agency correspondence, and follow-through across functions.
None of this proves a private-sector shortage on its own. It does, however, support a disciplined staffing view: regulatory work should be assessed by submission volume, milestone density, agency engagement requirements, and the scientific or operational complexity tied to each program.
Workload intensity can justify specialist support even without a large internal team
FDA’s workload estimates also show why some programs call for deeper expertise than a general compliance function can provide. In FY 2025, the agency reported average review-hour requirements of 7,849 hours for PDUFA NME and BLA applications and 2,922 hours for PDUFA non-NME applications, using a conversion of 2,080 workload hours to one full-time equivalent for that calculation.
Those figures describe FDA review effort, not sponsor staffing requirements. Still, they are a credible indicator of the complexity and scrutiny associated with different application types. For employers, that matters because the regulatory burden attached to a product, indication, or submission path is not uniform. A lean team that can manage routine labeling updates or established submission processes may not be set up for a novel program, a high-stakes meeting sequence, or a compressed filing timeline.
This is often the point at which regulatory consultants add value. The strongest use case is not replacing a team wholesale, but adding targeted capacity where the work requires a specific submission background, document strategy skill set, or ability to coordinate tightly with clinical, safety, quality, and manufacturing stakeholders.
Hiring plans and vacancies show that capacity planning is active work, even at the FDA
FDA’s FY 2025 reporting also shows that staffing capacity is actively managed, not assumed. Under the PDUFA commitment cited in the report, the agency said it planned to hire 352 full-time equivalents across FY 2023 through FY 2027. By September 30, 2025, 275 of those 352 positions had been filled, or 78 percent of the commitment.
At the same time, FDA reported 58 remaining vacancies tied to that commitment in FY 2025, including 24 in CDER and 34 in CBER. The report also listed 9 CDER hires and 15 CBER hires during FY 2025 under the same commitment. Separately, FDA reported a time-reporting population of 10,844 FTEs for whom time reporting was required and 2,343 FTEs for whom it was not required across several major entities.
These figures should not be overstated. They do not establish that vacancies were caused by workload pressure, nor do they measure private-sector recruiting conditions. But they do reinforce a useful point for employers: even in a large, structured regulatory environment, capacity depends on continuous planning, hiring, and deployment against real workload.
How employers should interpret the broader talent market
There is no BLS occupation that cleanly counts regulatory affairs specialists as a standalone national category. The nearest broad federal labor-market proxy is Compliance Officers, which BLS defines as workers who help ensure that organizations meet legal and regulatory requirements. That makes the category useful for context, but not as a direct measure of pharmaceutical, biotech, device, or healthcare regulatory-affairs talent.
Within that proxy category, BLS reports 436,400 compliance officers employed nationally in 2025, with median annual pay of $80,730 in May 2025. BLS projects employment of 453,100 by 2035, up 16,700 over the period, and estimates 32,700 openings per year on average from 2025 to 2035. BLS also lists a bachelor’s degree as the typical entry-level education requirement.
For recruitment leaders, the takeaway is nuance. Broad compliance data can help frame pay, competition, and baseline credential expectations, but regulatory affairs hiring still needs a more specific lens. The relevant question is whether a candidate has experience in the submission type, therapeutic area, product class, and agency-facing work your organization actually needs.
When regulatory affairs capacity becomes critical, the best response is usually more precise than “hire another generalist.” FDA’s own framework supports planning around forecast workload, role type, and timing, while current performance data show the scale and complexity of review-related activity. For healthcare and life sciences employers, that is the case for using regulatory consultants selectively and strategically: to cover submission-specific expertise, protect milestones, and give internal teams enough capacity to execute without avoidable delay.